SCHEMBL23945919

SCHEMBL23945919

CCOC(=O)c1cnn2c(C3CNCCCO3)cc(Cl)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.42
HSD17B10 Q99714 6/20 0.42
PLAT P00750 1/20 0.42
HPGD P15428 5/20 0.41
ALDH1A1 P00352 5/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CASP1 P29466 3/20 0.38
CASP7 P55210 2/20 0.38
TSHR P16473 1/20 0.38
MAPT P10636 2/20 0.38
GAA P10253 2/20 0.38
GLA P06280 1/20 0.38
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CSNK1D P48730 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13778074 0.73 KDM4E (0.55) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL17732301 0.73 KDM4E (0.65) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL24395078 0.72 KDM4E (0.54) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL19436634 0.71 KDM4E (0.53) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL20697186 0.71 KDM4E (0.53) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL20689018 0.70 KDM4E (0.52) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL23945689 0.70 KDM4E (0.41) KDM4EHSD17B10PLATHPGDALDH1A1
SCHEMBL25070256 0.69 KDM4E (0.51) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL19436637 0.69 KDM4E (0.50) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL30993477 0.69 KDM4E (0.50) KDM4EHSD17B10HPGDALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885HSD17B10 2107/4885PLAT 1236/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885HSD17B10 2107/4885PLAT 1236/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885HSD17B10 2107/4885PLAT 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.